Cellectar Biosciences
CLRB
19 hedge funds and large institutions have $734K invested in Cellectar Biosciences in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 19 closing their positions.
5.33% more ownership
Funds ownership: 0.38% → 5.71% (+5.3%)
41% less funds holding
Funds holding: 32 → 19 (-13)
55% less capital invested
Capital invested by funds: $1.63M → $734K (-$894K)
68% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 19
78% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$96.6K |
| 2 |
RCA
Riverview Capital Advisers
Boston,
Massachusetts
|
+$91.9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.71K |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
+$1.16K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$79 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$237K |
| 2 |
Squarepoint
New York
|
-$117K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$108K |
| 4 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
-$64.1K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$48.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Two Sigma Investments
New York
| – | -$26.2K | -2,770 | Closed |
|
27
Northern Trust
Chicago,
Illinois
| – | -$24.6K | -2,600 | Closed |
|
|
RWS
28
Rochester Wealth Strategies
Rochester,
Michigan
| – | -$13.6K | -1,433 | Closed |
|
|
ACM
29
ADAR1 Capital Management
Austin,
Texas
| – | -$12.7K | -1,341 | Closed |
|
|
NA
30
Nordwand Advisors
Radnor,
Pennsylvania
| – | -$6.31K | -667 | Closed |
|
|
VPIM
31
Vanguard Personalized Indexing Management
Oakland,
California
| – | -$5.54K | -586 | Closed |
|
|
OC
32
Oppenheimer & Co
New York
| – | -$3.94K | -417 | Closed |
|
33
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$4K | -402 | Closed |
|
34
Goldman Sachs
New York
| – | -$3.41K | -360 | Closed |
|
|
CB
35
Commerce Bank
Kansas City,
Missouri
| – | -$3.15K | -333 | Closed |
|
|
EWA
36
EverSource Wealth Advisors
Birmingham,
Alabama
| – | -$519 | -55 | Closed |
|
37
JP Morgan Chase
New York
| – | -$24 | -3 | Closed |
|
|
AWM
38
AllSquare Wealth Management
Albany,
New York
| – | -$6 | -1 | Closed |
|
CLRB Hedge Fund Activity: Q2 2025 in Review
19 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q2 2025, worth a combined $734K — down 55% from $1.63M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of CLRB and 6 opened new positions — a net loss of 13 holders — while 9 trimmed existing stakes and 2 added.
The largest buyer was HRT Financial, adding an estimated $96.6K. The largest seller was UBS Group, cutting an estimated $237K.
- 19 institutional investors held Cellectar Biosciences (CLRB) as of Q2 2025, down from 32 in Q1 2025.
- Funds reported $734K of Cellectar Biosciences stock for Q2 2025, down 55% quarter-over-quarter.
- 6 funds opened new Cellectar Biosciences positions in Q2 2025 and 19 closed out, a net change of -13 holders.
- The largest Cellectar Biosciences buyer in Q2 2025 was HRT Financial, an estimated $96.6K added.
- The largest Cellectar Biosciences seller in Q2 2025 was UBS Group, an estimated $237K sold.
Based on aggregated 13F filings for Q2 2025.